AI assistant
Sending…
Merck & Co., Inc. — Director's Dealing 2022
May 3, 2022
284_dirs_2022-05-03_4d9f0fcb-1b93-49e3-894d-212d19ec0257.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2022-05-01
Reporting Person: Oosthuizen Johannes Jacobus (SVP, U.S. Market)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-01 | Common Stock | M | 866 | $88.69 | Acquired | 14088.881 | Direct |
| 2022-05-01 | Common Stock | F | 427 | $88.69 | Disposed | 13661.881 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-05-01 | Restricted Stock Unit | $ | M | 866 | Disposed | 2023-05-01 | Common Stock (866) | Direct |
Footnotes
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
More from Merck & Co., Inc.
Regulatory Filings
2026
May 29
Declaration of Voting Results & Voting Rights Announcements
2026
May 28
Capital/Financing Update
2026
May 22
Capital/Financing Update
2026
May 20
Capital/Financing Update
2026
May 18
Capital/Financing Update
2026
May 18
Regulatory Filings
2026
May 13
Interim / Quarterly Report
2026
May 4
Major Shareholding Notification
2026
Apr 30
Earnings Release
2026
Apr 30